We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where BridgeBio Pharma Inc. (NASDAQ:BBIO) stands against the other stocks.

Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno ...

The company has debuted its newest venture—GondolaBio, a biopharma startup. It will focus on developing therapies for genetic and rare diseases. Overall BBIO ranks 12th on our list of the best ...

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $17.00. Discover outperforming stocks ...

Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play ...

and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of ...

For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several years – but fell to $1.6 billion across Q2 and Q3 combined ...

SAN FRANCISCO — The J.P. Morgan Healthcare Conference isn’t just a venue for companies in the industry to outline their plans for the year or tamp down questions about their finances.

By analyzing E. coli protein levels, scientists found a surplus of membrane shuttle proteins that may play a role in antibiotic resistance.

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion deal for the Chinese biopharma's phase 1 T-cell engager. Later during ...